A Multi-centre Phase III Study to Evaluate Preemptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Rituximab-based Chemotherapy for Non-Hodgkin's Lymphoma
The purpose of the study is to determine how effective preemptive tenofovir therapy is in
preventing the re-activation of Hepatitis B infection, in patients who are receiving
rituximab-based chemotherapy for Non-Hodgkin's Lymphoma. The rate of re-activation will be
compared between patients who receive preemptive tenofovir and patients who receive
tenofovir as needed.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society